title: [Macular toxoplasmosis and intravitreal clindamycin: an alternative to oral treatment].
authors.forename: S
authors.initials: S
authors.lastname: Martínez Castillo
authors.forename: R
authors.initials: R
authors.lastname: Gallego-Pinazo
authors.forename: E
authors.initials: E
authors.lastname: Francés-Muñoz
authors.forename: R
authors.initials: R
authors.lastname: Dolz-Marco
authors.forename: A
authors.initials: A
authors.lastname: Vázquez Polo
authors.forename: M
authors.initials: M
authors.lastname: Díaz-Llopis
mesh_terms: D000328:Adult; D000818:Animals; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002981:Clindamycin / Q000008:administration & dosage / Q000627:therapeutic use*; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008266:Macula Lutea / Q000469:parasitology*; D008297:Male; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D012164:Retinal Diseases / Q000188:drug therapy* / Q000469:parasitology; D041623:Tomography, Optical Coherence; D014126:Toxoplasmosis, Ocular / Q000188:drug therapy*
chemical_list: D000981:Antiprotozoal Agents; D002981:Clindamycin; D003907:Dexamethasone